Table 2.
Cohort | Person-Years of Follow-Up | All Malignancy | Hematologic Malignancy | ||
---|---|---|---|---|---|
Crude Rate per 100K person-years (95% CI) | Standardized Rate | Crude Rate per 100K person-years (95% CI) | Standardized Rate | ||
All children with JIA | 12,614 | 79.3 (42.7–147.3) | 79.3 | 23.8 (7.7–73.7) | 23.8 |
JIA unexposed | 5,671 | 105.8 (47.5–235.5) | 106.5 | 17.6 (2.5–125.1) | 21.1 |
JIA MTX without TNF inhibitor | 3,894 | 77.0 (24.8–238.8) | 75.9 | 51.3 (12.8–205.2) | 46.2 |
JIA any TNF inhibitor | 2,922 | 34.2 (4.8–242.9) | 37.0 | 0 (0–126.3) | (zero) |
Asthma | 675,794 | 28.6 (24.8–32.9) | 27.1 | 10.5 (8.3–13.3) | 10.4 |
ADHD | 391,984 | 17.4 (13.4–22.0) | 23.7 | 7.4 (5.1–10.6) | 9.3 |
SEER external control | --- | --- | 15.0 | --- | 6.1 |
JIA = juvenile idiopathic arthritis; ADHD = attention-deficit hyperactivity disorder; MTX = methotrexate or leflunomide; TNF inhibitor = etanercept, infliximab, or adalimumab; SEER = Surveillance Epidemiology and End Results